GuidelineThe Journal of urology2019
Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.
Guideline in The Journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05022914 (Prostate-Specific Membrane Antigen), which is not on this map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prostate-Specific Membrane Antigen (PSMA) Guided Approach for bIoCHEmical Relapse After Prostatectomy- A Prospective Observational Study-PSICHE
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Gender bias in shared decision-making among cancer care guidelines: A systematic review.Health expectations : an international journal of public participation in health care and health policy · 2023Pooled it
- Recommendations on Weight Loss and Healthy Lifestyle in Prostate Cancer Clinical Guidelines: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.Medical oncology (Northwood, London, England) · 2022Trial
- Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.Lancet (London, England) · 2020Trial
- Exploratory cost-effectiveness analysis ofClinical & experimental metastasis · 2020Trial
- Long-term Outcomes of Toxicities and Disease Control Following Postoperative Moderately Hypofractionated Radiotherapy in High-Risk Prostate Cancer: Results of a Prospective Study.Clinical and translational radiation oncology · 2026Article
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy.Future oncology (London, England) · 2026Observational
- Time to BCR and cancer-specific mortality after radiotherapy or prostatectomy: implications for risk stratification and follow-up.World journal of urology · 2026Article
- High-risk biochemical recurrence in prostate cancer: identification and early intervention strategies.Frontiers in urology · 2026Review
- Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial-NCT 05022914).La Radiologia medica · 2026Article
- Incidence and predictors of lower extremity lymphedema after postoperative radiotherapy for prostate cancer.Radiation oncology (London, England) · 2025Article
- How to tailor the radiotherapy after radical prostatectomy in the modern era of molecular imaging, genomic testing, and technology development?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
- Treatment decision regret after precision prostatectomy: An analysis of patient-reported outcomes predicting decision regret.BJUI compass · 2025Article
- Prognostic Significance of High-Risk versus Very High-Risk Classification in Non-Surgically Managed Prostate Cancer: A Retrospective Cohort Study.Cancer management and research · 2025Article
- Shaping Clinical Policy for Salvage Radiotherapy After Radical Prostatectomy in Prostate Cancer: Bridging the Gap Between Clinical Trials and Daily Practice.Cancer medicine · 2024Article
- The Association Between Lymphovascular or Perineural Invasion in Radical Prostatectomy Specimen and Biochemical Recurrence.Cancers · 2024Article
- The expanding role of radiation oncology across the prostate cancer continuum.Abdominal radiology (New York) · 2024Review
- Impact of Clinical Factors onAdvances in radiation oncology · 2024Article
- The Association between Patient Characteristics and Biochemical Recurrence after Radical Prostatectomy.Medicina (Kaunas, Lithuania) · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe purpose of this amendment is to incorporate newly-published literature into the original ASTRO/AUA Adjuvant and Salvage Radiotherapy after Prostatectomy Guideline and to provide an updated clinical framework for clinicians. MATERIALS AND
methodsThe original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published from January 1990 through December 2017. Two new key questions were added. One on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation post-radical prostatectomy.
resultsA new statement on the use of hormone therapy with salvage radiotherapy after radical prostatectomy was added and long-term data was used to update an existing statement on adjuvant radiotherapy. The balance of the guideline statements were re-affirmed and references were added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases was found.
conclusionsHormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage radiotherapy. The clinician should discuss possible short- and long-term side effects with the patient as well as the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multi-disciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.